Squamous cell carcinoma of the maxillary sinus: A Tata Memorial Hospital experience

Abstract

BACKGROUND:The optimal treatment of maxillary sinus carcinoma remains to be defined and there is a paucity of

Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary Sinus

“…This pattern of early locoregional failure is consistent with previous literature [9, 12, 22]. By reducing the bulk of the tumour, induction chemotherapy facilitates surgery and also reduces the area of high risk CTV (critical tumour volume) in radiation planning.…”

“…All these have been documented to be poor risk factors in the literature [6, 19]. Despite this, our 3-year OS of 35% is comparable to our own published literature [9]. Significantly, in our previous study, 37.5% of patients had positive margins after surgery while in the present analysis, there was no margin positivity despite all the patients having upfront technically unresectable tumour (Table 4).…”

“…Overall, the reported survival in these studies has been between 34 and 40% at 5 years [2, 4, 23]. A previously published study from our centre by Qureshi et al also reported a 3-year survival rate of 38% [9]. …”

“…There is a paucity of well-designed, large, and randomised studies specifically addressing maxillary cancers. As seen in Table 3, the studies are mostly retrospective case series which have low numbers, patients treated over decades, and both early and late stage carcinoma maxilla and include patients with malignancy of other paranasal sinuses [4–7, 9, 12, 15–22]. The available data suggests that in locally advanced tumours, surgery followed by radiation leads to better outcomes than radical radiation alone [5–8, 12].…”

“…These patients have traditionally been treated with radical radiotherapy, with or without concurrent chemotherapy. The 5-year overall survival in this subgroup of patients is dismal, around 9–25% [7, 9, 12]. Considering such results, there is an urgent need for a new treatment paradigm for patients with maxillary carcinomas, especially in patents with unresectable disease or those who will require morbid resections.…”